The ongoing phase 3 trial EA8212 (BRIDGE) is enrolling patients with early-stage bladder cancer to compare gemcitabine+docetaxel chemotherapy (GEMDOCE) to standard first-line bacillus Calmette-Guerin (BCG) immunotherapy. Study chair Max Kates, MD (Johns Hopkins University) and colleagues discuss the study, including the preliminary data on GEMDOCE justifying it, in a new Clinical Studies Update in European Urology Focus.
While BCG provides long-term recurrence-free survival for some patients, 30-50% will have a recurrence within 2 years. In addition, there are dose-limiting toxicities with BCG and unpredictable access due to manufacturing issues and increased global demand. During the BCG shortages, many urologists have turned to GEMDOCE as a replacement. BRIDGE is a necessary next step in demonstrating the non-inferiority of the GEMDOCE regimen compared to BCG in the frontline setting.
This article is best read on the publication's website by following this link (subscription required).
Learn more about the BRIDGE trial on ecog-acrin.org.